Misplaced Pages

Elvitegravir

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 00:25, 1 July 2011 (Updating {{drugbox}} (changes to verified fields - updated 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 00:25, 1 July 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Elvitegravir
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 6--1--7-methoxy-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H23ClFNO5
Molar mass447.883 g/mol g·mol
3D model (JSmol)
SMILES
  • Clc1cccc(c1F)Cc3c(OC)cc2c(C(=O)\C(=C/N2(CO)C(C)C)C(=O)O)c3
InChI
  • InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
  • Key:JUZYLCPPVHEVSV-LJQANCHMSA-N
  (what is this?)  (verify)

Elvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.

According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.

References

  1. Gilead Press Release Phase III Clinical Trial of Elvitegravir July 22, 2008
  2. Gilead Press Release Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor March 22, 2008
  3. Shimura K, Kodama E, Sakagami Y; et al. (2007). "Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137)". J Virol. 82 (2): 764. doi:10.1128/JVI.01534-07. PMC 2224569. PMID 17977962. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  4. Stellbrink HJ (2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
  5. Thaczuk, Derek and Carter, Micheal. ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents Aidsmap.com. 19 Sept. 2007.
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Elvitegravir Add topic